Certolizumab pegol: A review of its use in the management of rheumatoid arthritis

Drugs

Volumn 73, Issue 1, 2013, Pages 75-97

  Deeks, Emma D ^a  

^a Adis 41 ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB;

DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84876267546     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0009-3     Document Type: Review

References (100)

1. Centers for Disease Control and Prevention. Rheumatoid arthritis. 2012. http://www.cdc.gov/arthritis/basics/rheumatoid.htm. Accessed 2 Oct 2012.
2. World Health Organization. Chronic diseases and health promotion: chronic rheumatic conditions. 2012. http://www.who.int/chp/topics/rheumatic/en/. Accessed 2 Oct 2012.
3. Asia Pacific League of Associations for Rheumatology. Rheumatoid arthritis: facts and figures. 2012. http://www.aplar.org/Education/Documents/ FINAL-EDC-Fact-Sheet.pdf. Accessed 4 Oct 2012.
4. Ngian GS. Rheumatoid arthritis. Aust Fam Phys. 2010;39(9):626-8.
5. Infusion Nurses Society. Rheumatoid arthritis: epidemiology, symptomatology, and natural history of the disease process. Counseling points™. 2007;1(1):1-15.
6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-75.
7. Geyer M, Muller-Ladner U. Rationale of using different biological therapies in rheumatoid arthritis. Arthr Res Ther. 2010;12(4):214.
8. Wijesinghe H, Seneviratne SL, Galappatthy P, et al. Biologics: a new weapon in the war against autoimmune joint disease. J Ceylon Coll Phys. 2010;41:76-82.
9. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355(7):704-12.
10. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.
11. UCB, Inc. Cimzia (certolizumab pegol) lyophilized powder or solution for subcutaneous use: US prescribing information. 2012. http://www.accessdata.fda. gov/drugsatfda-docs/label/2012/125160s189lbl.pdf. Accessed 14 Dec 2012.
12. UCB Pharma S.A. Cimzia 200 mg solution for injection: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/001037/WC500069763.pdf. Accessed 14 Dec 2012.
13. Duggan ST, Keam SJ. Certolizumab pegol: in rheumatoid arthritis. BioDrugs. 2009;23(6):407-17.
14. Lamour S, Bracher M, Nesbitt A. The PEG component of certolizumab pegol inhibits degranulation by stimulated mast cells (abstract). Arthr Rheum. 2009;60(Suppl.):44.
15. Heathfield SK, Bruce I, Alexander MY. Certolizumab pegol inhibits tumour necrosis factor-induced endothelial cell activation (abstract no. 10). Heart. 2011;97(20):5-6.
16. d'Hauterive SP, Kesseler S, Ruggeri P, et al. Certolizumab pegol did not result in a decrease in semen quality in healthy volunteers: results from a phase 1 study (abstract no. FRI0160). Ann Rheum Dis. 2012;71(Suppl. 3):365.
17. FDA Center for Drug Evaluation and Research. Application number: BLA 125160/0. Pharmacology review(s). 2008. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2008/125160s000-PharmR-P1.pdf. Accessed 14 Dec 2012.
18. Barnes T, Moots R. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Int J Nanomed. 2007;2(1):3-7.
19. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13(11):1323-32.
20. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68(6):805-11.
21. Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford). 2012;51(7):1226-34.
22. Keystone E, van der Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthr Rheum. 2008;58(11):3319-29.
23. Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804.
24. Parton T, King L, Parker G, et al. The PEG moiety of certolizumab pegol is rapidly cleared from the blood of humans by the kidneys once it is cleaved from the Fab′ (abstract no. THU0051). Ann Rheum Dis. 2009;68(Suppl. 3):189.
25. Wolf D, Mahadevan U. Certolizumab pegol use in pregnancy: low levels detected in cord blood (abstract no. 718). Arthr Rheum. 2010;62(10 Suppl.):S299.
26. Clowse M, Wolf DC, Stach C, et al. Outcomes of pregnancy in subjects exposed to certolizumab pegol (abstract no. 1643). Arthr Rheum. 2012;64(10 Suppl.):S702.
27. Furst DE, Shaikh SA, Greenwald M, et al. Evaluation of two dosing regimens of certolizumab pegol for maintenance of clinical response in patients with active rheumatoid arthritis: primary results from DOSEFLEX, a phase IIIb study (abstract no. SAT0126). Ann Rheum Dis. 2012;71(Suppl. 3):513.
28. Kang YM, Park W, Park YE, et al. Efficacy and safety of certolizumab pegol (CZP) with concomitant methotrexate (MTX) in Korean rheumatoid arthritis (RA) patients (pts) with an inadequate response to MTX (abstract no. AB0501). Ann Rheum Dis. 2012;71(Suppl. 3):666.
29. Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate (abstract no. 1218). Arthr Rheum. 2011;63(10 Suppl. 1):S474-5.
30. Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis (abstract no. 1220). Arthr Rheum. 2011;63(10 Suppl.):S476.
31. Weinblatt ME, Fleischmann R, Huizinga TWJ, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford). 2012;51(12):2204-14.
32. Smolen JS, Emery P, Ferraccioli GF, et al. Efficacy and safety of certolizumab pegol after incomplete response to DMARDs in RA patients with low moderate disease activity: results from CERTAIN, a phase IIIb study (abstract no. THU0244). 12th Annual Congress of the European League Against Rheumatism, London, 25-28 May 2011.
33. Fleischmann RM, Choy E, Van Vollenhoven R, et al. Safety, efficacy, and sustained improvements in household productivity and daily activities with certolizumab pegol (CZP) monotherapy over 2 years in patients with active rheumatoid arthritis (RA) (abstract no. 1832). Arthr Rheum. 2010;62(10 Suppl.):S765-6.
34. Strand V, Purcaru O, van Vollenhoven RF, et al. Long-term benefits of 4-weekly certolizumab pegol combination and monotherapy on household productivity and social participation in rheumatoid arthritis: 5 year results from an open-label extension study (abstract no. 1318). Arthr Rheum. 2012;64(10 Suppl.):S567.
35. Smolen J, Van Vollenhoven R, Kavanaugh A, et al. Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the rapid 2 study (abstract). Rheumatology (Oxford). 2011;50(Suppl. 3):iii123.
36. Strand V, Fleischmann R, Kvien TK, et al. Certolizumab pegol (CZP) added to methotrexate (MTX) provides lasting improvements in patient-reported outcomes (PROs) over 2 years (abstract no. 1698). 73rd annual scientific meeting of the American College of Rheumatology and the 44th annual meeting of the Association of Rheumatology Health Professionals, Philadelphia (PA), 16-21 Oct 2009.
37. Keystone EC, van der Heijde DMFM, Smolen JS, et al. Open-label certolizumab pegol is effective in patients who withdrew from double-blind treatment due to non-response (abstract no. 1697). 73rd annual scientific meeting of the American College of Rheumatology and the 44th annual meeting of the Association of Rheumatology Health Professionals, Pennsylvania (PA), 16-21 Oct 2009.
38. Westhovens R, Strand V, Keystone E, et al. A faster clinical response to certolizumab pegol treatment is associated with better improvements in household productivity in patients with rheumatoid arthritis (abstract). J Rheumatol. 2010;37(6 Suppl. 2):1292-3.
39. Schiff M, Davies O, Bennett B, et al. Certolizumab pegol plus methotrexate is similarly effective in active rheumatoid arthritis regardless of prior TNF inhibitor use: analysis of the DOSEFLEX phase IIIb study (abstract no. AB0480). Ann Rheum Dis. 2012;71(Suppl. 3):665.
40. Yamanaka H, Yamamoto K, Takeuchi T, et al. Improved physical function, pain, and health related quality of life with certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: results from the JRAPID study (abstract no. AB0468). Ann Rheum Dis. 2012;71(Suppl. 3):664.
41. Yamanaka H, Yamamoto K, Takeuchi T, et al. Improved physical function, pain, and health related quality of life with certolizumab pegol in Japanese rheumatoid arthritis patients without methotrexate co-administration: results from the HIKARI study (abstract no. AB0469). Ann Rheum Dis. 2012;71(Suppl. 3):664.
42. Pope J, Fleischmann R, Dougados M, et al. Rapid reductions in fatigue and sleep problems and correlation with improvements in patient-reported outcomes in patients with active RA treated with certolizumab pegol in the REALISTIC 12-week phase IIIb randomised controlled study (abstract no. PMS61). Value Health. 2011;14:A313.
43. Weinblatt M, Fleischmann RM, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: week 28 results from a phase IIIb randomized controlled study (abstract no. 1253). Arthr Rheum. 2011;63(10 Suppl. 1):1-2.
44. Burmester G, Müller-Ladner U, Nüsslein H, et al. Rapid achievement of remission with certolizumab pegol was maintained for one year: interim results from FAST, a German non-interventional study in rheumatoid arthritis real life patients (abstract no. AB0467). Ann Rheum Dis. 2012;71(Suppl. 3):664.
45. Chatzidionysiou K, van Vollenhoven R. Treatment with certolizumab pegol in RA: data from the national registry ARTIS (Antirheumatic Therapies in Sweden) (abstract no. SAT0137). Ann Rheum Dis. 2012;71(Suppl. 3):517.
46. Fleischmann R, van Vollenhoven R, Vencovsky J, et al. Long-term safety of 4-weekly certolizumab pegol in rheumatoid arthritis: 5 year results from an open label extension study (abstract no. SAT0151). Ann Rheum Dis. 2012;71(Suppl. 3):523.
47. Weinblatt M, Fleischmann R, Davies O. Timing and magnitude of initial response to certolizumab pegol in a broad population of patients with active rheumatoid arthritis predicts likelihood of LDA at week 28 (abstract no. SAT0145). Ann Rheum Dis. 2012;71(Suppl. 3):520.
48. Strand V, Mease P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthr Res Ther. 2009;11(6):R170.
49. Strand V, Smolen JS, van Vollenhoven RF, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis. 2011;70(6):996-1002.
50. Kavanaugh A, Smolen JS, Emery P, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis (published erratum appears in Arthritis Rheum. 2010 Oct; 62(10):1514). Arthr Rheum. 2009;61(11):1592-600.
51. Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford). 2012;51(9):1628-38.
52. Curtis JR, Chen L, Luijtens K, et al. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthr Rheum. 2011;63(8):2203-8.
53. Keystone EC, Curtis JR, Fleischmann RM, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol. 2011;38(6):990-6.
54. Van Der Heijde D, Keystone EC, Curtis JR, et al. Timing and magnitude of initial change in Disease Activity Score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol. 2012;39(7):1326-33.
55. Hazes JM, Taylor P, Strand V, et al. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford). 2010;49(10):1900-10.
56. US National Institutes of Health. ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 29 Oct 2012.
57. Mariette X, van Vollenhoven RF, Bykerk VP, et al. Safety update on certolizumab pegol in patients with active rheumatoid arthritis with long term exposure (abstract no. 503). Arthr Rheum. 2012;64(10 Suppl.):S221.
58. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(Suppl. 1):1-12.
59. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-7.
60. Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559-82.
61. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthr Care Res (Hoboken). 2012;64(5):625-39.
62. Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthr Res Ther. 2011;13(Suppl. 1):S3.
63. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9 Suppl. B):S14-8.
64. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis. 2004;63:627-33.
65. Balsa A, García-Arias M. Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis? Ther Adv Musculoskelet Dis. 2010;2(6):307-13.
66. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315-29.
67. Immunex Corporation. Enbrel (etanercept) for subcutaneous injection: US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/103795s5503lbl.pdf. Accessed 14 Dec 2012.
68. Pfizer Limited. Enbrel: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000262/WC500027361.pdf. Accessed 14 Dec 2012.
69. Bristol-Myers Squibb Company. Orencia (abatacept): US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 125118s0138lbl.pdf. Accessed 14 Dec 2012.
70. Swedish Orphan Biovitrum AB (publ). Kineret (anakinra): US prescribing information. 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 103950s5116lbl.pdf. Accessed 14 Dec 2012.
71. Swedish Orphan Biovitrum AB (publ). Kineret: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000363/WC500042310.pdf. Accessed 14 Dec 2012.
72. Janssen Biotech Inc. Remicade (infliximab): US prescribing information. 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/103772s5295lbl. pdf. Accessed 14 Dec 2012.
73. Janssen Biologics B.V. Remicade: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000240/WC500050888.pdf. Accessed 14 Dec 2012.
74. Biogen Idec Inc. and Genentech Inc. Rituxan (rituximab): US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 103705s5367s5388lbl.pdf. Accessed 14 Dec 2012.
75. Roche Registration Limited. MabThera: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000165/WC500025821.pdf. Accessed 14 Dec 2012.
76. Khan A, Scott DL. Certolizumab in the long-term treatment of rheumatoid arthritis. Open Access Rheumatol Res Rev. 2011;3:63-71.
77. Tak PP. Understanding drug resistance to biologic therapy. A personalized medicine approach to biological treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford). 2012;51(4):600-9.
78. Schiff M, Goldblum R, Tesser J. Can rheumatoid arthritis (Ra) incomplete secondary responders to TNF-alpha attain an efficacious and safe response by switching to certolizumab pegol? (abstract no. SAT0144). 13th Annual Congress of the European League Against Rheumatism, Berlin, 6-9 Jun 2012.
79. Cush JJ, Kay J, Dao KH. Does rheumatoid arthritis or biologic therapy increase cancer risk? Drug Safety Quarterly. 2012;4(2):1-7.
80. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl. 5):v38-47.
81. Le Blay P, Mouterde G, Barnetche T, et al. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol. 2012;39(4):712-5.
82. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898-908.
83. Park HJ, Ranganathan P. TNF-α antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted? Discov Med. 2012;13(70):229-34.
84. Onel KB, Onel K. Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthr Care Res. 2010;62(7):1024-8.
85. Yazici Y. Safety reporting in randomized clinical trials: a need for improvement. Bull NYU Hosp Jt Dis. 2009;67(2):209-10.
86. Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol. 2011;38(5):835-45.
87. Péntek M, Gulácsi L, Érsek K, et al. Comparison of recently registered biological drugs with available therapies in rheumatoid arthritis: methodological issues to consider for meta-analysis (abstract no. PMS6). Value Health. 2010;13(7):A303.
88. National Institute for Health and Clinical Excellence. Certolizumab pegol for the treatment of rheumatoid arthritis: NICE technology appraisal guidance 186. 2010. http://www.nice.org.uk/nicemedia/live/12808/47544/47544.pdf. Accessed 2 Oct 2012.
89. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane review. Cochrane Database Syst Rev. 2011;(2):CD008794.
90. Malaviya AP, Östör AJK. Drug adherence to biologic DMARDs with a special emphasis on the benefits of subcutaneous abatacept. Patient Pref Adherence. 2012;6:589-96.
91. Abbott Laboratories. Humira (adalimumab): US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125057s232lbl. pdf. Accessed 14 Dec 2012.
92. Abbott Laboratories Ltd. Humira: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000481/WC500050870.pdf. Accessed 14 Dec 2012.
93. Janssen Biotech Inc. Simponi (golimumab): US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125289s070lbl. pdf. Accessed 14 Dec 2012.
94. Janssen Biologics B.V. Simponi: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000992/WC500052368.pdf. Accessed 14 Dec 2012.
95. ®. 2012. http://www.cimzia.com/rheumatoidarthritis/taking-cimzia. Accessed 28 Nov 2012.
96. Purcaru O, Taylor P, Emery P, et al. Cost-effectiveness of certolizumab pegol plus methotrexate or as monotherapy for the treatment of active rheumatoid arthritis in the United Kingdom (abstract no. AB0977). Ann Rheum Dis. 2010;69(Suppl. 3):718.
97. Villoro R, Hidalgo A, Ferro B, et al. Cost-utility analysis of certolizumab pegol versus alternative tumor necrosis factor-inhibitors, for the treatment of moderate-to-severe rheumatoid arthritis in Spain (abstract). Value Health. 2011;14(7):A310-1.
98. Maniadakis N, Boumpas D, Kourlaba G, et al. Cost-utility and budget impact analysis of certolizumab pegol plus methotrexate for the treatment of moderate-to-severe active rheumatoid arthritis in Greece (abstract). Value Health. 2011;14(7):A310.
99. Soini EJ, Hallinen T, Taiha M, et al. Cost-effectiveness, value of information, and budget impact of certolizumab pegol compared to subcutaneous tumor necrosis factor (TNF) inhibitors and methotrexate in the treatment of moderate-to-severe rheumatoid arthritis in Finland (abstract). Value Health. 2010;13(7):A243.
100. National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. 2007. http://www.nice.org.uk/nicemedia/live/11867/37914/37914.pdf. Accessed 5 Oct 2012.